DOCSLIB.ORG

Acta Okl1-2014.Cdr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ACTA POLONIAE PHARMACEUTICA VOL. 72 No. 6 November/December 2015 ISSN 2353-5288 Drug Research EDITOR Aleksander P. Mazurek National Medicines Institute, The Medical University of Warsaw ASSISTANT EDITOR Jacek Bojarski Medical College, Jagiellonian University, KrakÛw EXECUTIVE EDITORIAL BOARD Miros≥awa Furmanowa The Medical University of Warsaw Boøenna Gutkowska The Medical University of Warsaw Roman Kaliszan The Medical University of GdaÒsk Jan Pachecka The Medical University of Warsaw Jan Pawlaczyk K. Marcinkowski University of Medical Sciences, PoznaÒ Janusz Pluta The Medical University of Wroc≥aw Witold Wieniawski Polish Pharmaceutical Society, Warsaw Pavel Komarek Czech Pharmaceutical Society Henry Ostrowski-Meissner Charles Sturt University, Sydney Erhard Rˆder Pharmazeutisches Institut der Universit‰t, Bonn Phil Skolnick DOV Pharmaceutical, Inc. Zolt·n Vincze Semmelweis University of Medicine, Budapest This Journal is published bimonthly by the Polish Pharmaceutical Society (Issued since 1937) The paper version of the Publisher magazine is a prime version. The electronic version can be found in the Internet on page www.actapoloniaepharmaceutica.pl An access to the journal in its electronics version is free of charge Impact factor (2014): 0.737 MNiSW score (2013): 15 points Index Copernicus (2014): 14.75 Charges Annual subscription rate for 2016 is US $ 210 including postage and handling charges. Prices subject to change. Back issues of previously published volumes are available directly from Polish Pharmaceutical Society, 16 D≥uga St., 00-238 Warsaw, Poland. Payment should be made either by bankerís draft (money order) issued to ÑPTFarmî or to our account Millennium S.A. No. 29 1160 2202 0000 0000 2770 0281, Polskie Towarzystwo Farmaceutyczne, ul. D≥uga 16, 00-238 Warszawa, Poland, with the memo Acta Poloniae Pharmaceutica - Drug Research. Warunki prenumeraty Czasopismo Acta Poloniae Pharmaceutica - Drug Research wydaje i kolportaø prowadzi Polskie Towarzystwo Farmaceutyczne, ul. D≥uga 16, 00-238 Warszawa. Cena prenumeraty krajowej za rocznik 2016 wynosi 207,90 z≥ (w tym 5% VAT). PrenumeratÍ naleøy wp≥acaÊ w dowol- nym banku lub UrzÍdzie Pocztowym na rachunek bankowy Wydawcy: Millennium S.A. 29 1160 2202 0000 0000 2770 0281 Polskie Towarzystwo Farmaceutyczne ul. D≥uga 16, 00-238 Warszawa z dopiskiem: prenumerata Acta Poloniae Pharmaceutica - Drug Research. Warunki prenumeraty zagranicznej - patrz tekst angielski. Typeset by RADIUS, Warszawa; Printed by Oficyna Wydawniczo-Poligraficzna Prestige, Zπbki Acta Poloniae Pharmaceutica ñ Drug Research Volume 72, Number 6 November/December 2015 CONTENTS REVIEW 1059. Syed Majid Bukhari, Iftikhar Ali, Asma Zaidi, Pharmacology and synthesis of daurichromenic acid as a Naseem Iqbal, Tayyaba Noor, Rashad Mehmood, potent anti-HIV agent. Muhammad Salman Chishti, Basit Niaz, Umer Rashid, Muhammad Atif 1073. Mingwei Mou, Chungen Li, Minghua Huang, Antiosteoporotic effect of the rhizome of Drynaria fortunei Ziyi Zhao, Huadong Ling, Xiang Zhang, (Kunze) (Polypodiaceae) with special emphasis on its modes Fengxian Wang, Xincheng Yin, Yanxu Ma of action. ANALYSIS 1081. Robert Piech, Beata Paczosa-Bator Application of glassy carbon electrode modified with naftion/MWCNTS for sensitive voltammetric determination of thymol. 1089. Kamil Kuú, Agnieszka Zakrzewska, Maria Walczak, Validation of LC/MS/MS method for assessment of the in vitro Ma≥gorzata Szafarz, Anna Gonciarz, Agnieszka Kij, activity of the selected rat cytochrome P450 isoenzymes - Joanna Suraj, Joanna Szymura-Oleksiak application to early drug metabolism screening. 1101. Urszula Hubicka, Pawe≥ Ømudzki, Barbara Øuromska- Determination and characterization of selected fluoroquinolones Witek, Pawe≥ Zajdel, Jan Krzek oxidation products under potassium permanganate treatment. 1115. Wei Chen, Lin Li, Tuling Lu, Baochang Cai, Development of a quality control method for Schisandrae Fangzhou Yin, Wu Yin Chinensis Fructus with micellar electrokinetic capillary chromatography. 1125. Renata Paprocka, Boøena Modzelewska-Banachiewicz Determination of lipophilicity parameters of new derivatives of N3 substituted amidrazones by reversed phase thin-layer chromatography. 1133. Pawe≥ Olczyk, Katarzyna Komosinska-Vassev, Application of electron paramagnetic resonance spectroscopy for Pawe≥ Ramos, £ukasz Mencner, Krystyna Olczyk, examination of free radical scavenging properties of insulin Barbara Pilawa analogs. 1141. Ma≥gorzata Do≥owy, Alina Pyka The effect of β-cyclodextrin on the resolution of free and conjugated forms of deoxycholic and chenodeoxycholic acids by TLC-densitometry. DRUG BIOCHEMISTRY 1151. Anna Pude≥ko, Ewa Obuchowicz Desipramine, fluoxetine and tranylcypromine have different effects on apoptosis induced in rat cortical neurons by oxygen- glucose deprivation. 1163. Agnieszka Bia≥ek, Andrzej Tokarz, Pawe≥ Zagrodzki Conjugated linoleic acids (CLA) decrease the breast cancer risk in DMBA-treated rats. 1177. Pawe≥ Olczyk, Katarzyna Komosinska-Vassev, Interactions of Insuman Comb 25 insulin with free radicals - Pawe≥ Ramos, Krystyna Olczyk, Barbara Pilawa kinetics examination by electron paramagnetic resonance spectroscopy. DRUG SYNTHESIS 1183. Saleh I. Alqasoumi, Mansour S. Alsaid, Maged S. Semisynthesis of novel sulfonamides, thioureas, and Abdel-Kader, Mostafa M. Ghorab biphenylsulfones as a new class of anticancer agents by using L-norephedrine as strategic starting material. 1193. Korany A. Ali, Mohamed A. Elsayed, Salwa Synthesis and antitumor screening of some new 2,6-bispyridines M. Elhallouty, Khaled Mahmoud, Ahmad M. Farag functionalized with pyrazole-based heterocycles. APPHAX 72 (6) 1057 ñ 1320 (2015) NATURAL DRUGS 1201. Aminu Mohammed, Neil Anthony Koorbanally, Phytochemistry, anti-oxidative and anti-diabetic effects of various Md. Shahidul Islam parts of Eugenia caryophyllata Thunb. in vitro. 1217. Agnieszka Kicel, Monika Anna Olszewska, Preliminary study on the composition of volatile fraction of fresh Aleksandra Owczarek, Maria Wolbiú flowers and leaves of Robinia pseudoacacia L. growing in Poland. 1223. Youshan Li, Qi Zheng, Jianhui Qin Effect of TCM Yinhuangsan on rat's diabetic ulcer healing morphology and recovery factors. 1233. Imran Shair Mohammad, Haji Muhammad Shoaib Khan, In vitro characterization and assessment of cosmetic potentials of Atif Iqbal Arshad, Hira Ijaz, Parikshit Banerjee, W/O emulsion cream containing 2% Prosopis cineraria extract. Asif Ullah Khan, Aftab-Ullah, Ajkia Zaman Juthi 1239. Aleksandra Owczarek, Jan Gudej, Monika Anna Antioxidant activity of Geum rivale L. and Geum urbanum L. Olszewska PHARMACEUTICAL TECHNOLOGY 1245. Ramzi Shawahna, Mashhour Ghanem, Ayat Ghanem, Establishing similarity between multisource betahistine Abdul-Fattah Mansour, Nema Ahmad, Abdel Naser Zaid hydrochloride oral dosage forms using in vitro methods. 1253. Przemys≥aw Zalewski, Daria Szymanowska-Powa≥owska, The radiolytic studies of ceftriaxone in the solid state. Piotr Garbacki, Magdalena Paczkowska, Alicja TalaczyÒska, Judyta Cielecka-Piontek 1259. Valentyn V. Mohylyuk, Lena L. Davtian Interaction of weak base drug trimetazidine and carbopol as further retardation in the matrix tablet. 1263. Przemys≥aw Zalewski, Robert SkibiÒski, Alicja Kinetics and mechanism of degradation of cefozopran TalaczyÒska, Magdalena Paczkowska, Piotr Garbacki, hydrochloride in the solid state. Judyta Cielecka-Piontek, Anna JeliÒska PHARMACOLOGY 1269. Mohammad Ayaz, Fazal Subhan, Jawad Ahmed, Citalopram and venlafaxine differentially augments antimicrobial Arif-ullah Khan, Farhat Ullah, Abdul Sadiq, properties of antibiotics. Nawazish-i-Husain Syed, Ihsan Ullah, Sajid Hussain 1279. Ewelina Dziurkowska, Marek Weso≥owski, Changes of salivary cortisol level after venlafaxine treatment. Maciej Dziurkowski GENERAL 1289. M·rton Argay, Andrea MeskÛ, Rom·na ZelkÛ, Therapy reminder message for Hungarian patients with type 2 Bal·zs HankÛ diabetes. 1295. Daniela Minarikova, Adamos Panayotis Electronic prescription services system in Greece - pilot study. 1303. Mariola Drozd, Kazimierz Drozd, Monika Safety of OTC analgesic drugs in the opinion of Polish patients - Szkultecka-DÍbek, Anna Kijewska, Nina Kiepurska preliminary study. SHORT COMMUNICATION 1315. Abdulmohsen H. Al Rohaimi Neuropharmacological and toxicity study of newly prepared N-[5- (3-chloro-4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-2-substituted acetamides. Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 72 No. 6 pp. 1059ñ1071, 2015 ISSN 0001-6837 Polish Pharmaceutical Society REVIEW PHARMACOLOGY AND SYNTHESIS OF DAURICHROMENIC ACID AS A POTENT ANTI-HIV AGENT SYED MAJID BUKHARI1*, IFTIKHAR ALI2, ASMA ZAIDI1, NASEEM IQBAL3, TAYYABA NOOR4, RASHAD MEHMOOD5, MUHAMMAD SALMAN CHISHTI6, BASIT NIAZ7, UMER RASHID7 and MUHAMMAD ATIF8 1 Department of Chemistry, COMSATS IIT, Abbotabad-22060, Pakistan 2 Department of Chemistry, Karakorum International University, Gilgit, Pa Islamabad-44000, Pakistan 4 School of Chemical and Materials Engineering (SCME), NUST, Islamabad-44000, Pakistan 5 Department of Conservation Studies, 6 Department of Biochemistry, 7 Department of Chemistry, Hazara University, Mansehra-21120, Pakistan 8 University of Education Lahore, Punjab, Pakistan Abstract: Daurichromenic acid (a potent anti-HIV agent) has been surveyed in this review article, not only for its pharmacological assessment comparative to other compounds but also for methodological trends in differ- ent synthetic approaches. Keywords: anti-HIV, 2H-chromen, total synthesis Acquired Immunity Deficiency Syndrome
Recommended publications
  • Treatment Effect of Bushen Huayu Extract on Postmenopausal Osteoporosis in Vivo

    Treatment Effect of Bushen Huayu Extract on Postmenopausal Osteoporosis in Vivo

    EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 1687-1690, 2014 Treatment effect of Bushen Huayu extract on postmenopausal osteoporosis in vivo LU OUYANG1,2, QIUFANG ZHANG1,2,3, XUZHI RUAN3, YIBIN FENG4 and XUANBIN WANG1,2 1Laboratory of Chinese Herbal Pharmacology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000; 2School of Pharmacy; 3Basic School of Medicine, Hubei University of Medicine, Shiyan, Hubei 442000; 4School of Chinese Medicine, LKS Faculty, The University of Hong Kong, Hong Kong, SAR, P.R. China Received December 2, 2013; Accepted March 25, 2014 DOI: 10.3892/etm.2014.1661 Abstract. Bushen Huayu extract (BSHY), a traditional Chinese model group (14.75±2.38; P<0.05), and decrease the number medicine, has been demonstrated to treat postmenopausal of osteoclasts in the BSHY-L, BSHY-M and BSHY-H groups osteoporosis, however, the underlying mechanism remains (4.00±1.85, 4.25±1.39 and 5.75±1.49, respectively) compared to be fully elucidated. The aim of the present study was to with 9.50±1.60 observed in the model group (P<0.05). These investigate the therapeutic effect of BSHY and the mecha- results suggest that BSHY is a potential therapeutic drug for nisms underlying this effect in an in vivo postmenopausal the treatment of osteoporosis in vivo. Furthermore, these results osteoporosis animal model. A total of 1 g BSHY containing suggest that the mechanism by which BSHY decreases the 7.12 µg icariin was prepared. Low-dose BSHY (BSHY-L; serum levels of IL-6 may be by regulating E2. 11.1 g/kg), medium-dose BSHY (BSHY-M; 22.2 g/kg) and high-dose BSHY (BSHY-H; 44.4 g/kg) was administered to Introduction oophorectomized rats using intragastric infusion.
  • View of Our Data Collection Tool

    View of Our Data Collection Tool

    University of Alberta Pharmacists’ Beliefs about Bioidentical Hormone Therapy by Tasneem Siyam A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science in Pharmacy practice Faculty of Pharmacy and Pharmaceutical Sciences © Tasneem Siyam Spring 2012 Edmonton, Alberta Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission. ABSTRACT OBJECTIVE: To identify pharmacists’ beliefs about bioidentical hormone therapy (BHT) and determine factors influencing these beliefs. METHODS: This was a cross-sectional survey targeting practicing pharmacists in Alberta. Participants completed a 54-item, online questionnaire, designed to capture their demographics, as well as their beliefs about BHT. Summary statistics and multivariate regression were used for analyses. Qualitative components were analyzed using phenomenological approach. RESULTS: Over half of respondents believed BHT had equal efficacy and risks as non-bioidentical hormones. Beliefs on estriol, natural progesterone, and saliva testing however, were more diverse with many do not know responses (40%). In multivariate analysis, BHT compounding practice was associated with beliefs about BHT.
  • 192435859.Pdf

    192435859.Pdf

    European Journal of Pharmacology 691 (2012) 275–282 Contents lists available at SciVerse ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Endocrine pharmacology Egonol gentiobioside and egonol gentiotrioside from Styrax perkinsiae promote the biosynthesis of estrogen by aromatase Danfeng Lu, Lijuan Yang, Qilin Li, Xiaoping Gao, Fei Wang n, Guolin Zhang nn Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, PR China article info abstract Article history: Estrogen deficiency is associated with a variety of diseases, including osteoporosis, atherosclerosis, and Received 11 May 2012 Alzheimer’s disease. Aromatase cytochrome P450 is the only enzyme in vertebrates known to catalyze Received in revised form the biosynthesis of estrogens from androgens. Inhibitors of aromatase have been developed for the 2 July 2012 treatment of estrogen-dependent breast cancer. However, small molecular agonists of aromatase, Accepted 2 July 2012 which would be useful to locally promote estrogen biosynthesis for the prevention of estrogen Available online 13 July 2012 deficiency-induced diseases, are rarely reported. In this study, we established a nonradioactive assay Keywords: for measuring aromatase activity by using human ovarian granulosa KGN cells and identified two Egonol estrogen biosynthesis-promoting compounds, egonol gentiobioside and egonol gentiotrioside from Estrogen Styrax perkinsiae. The compounds also promoted estrogen biosynthesis in 3T3-L1 preadipocyte cells. Aromatase Further study showed that neither compound affected the transcriptional and translational expression Styrax perkinsiae KGN cell line of aromatase in KGN cells, but that both significantly promoted the in vitro enzyme activity of recombinant expressed aromatase. Egonol gentiotrioside was also found to increase the serum estrogen level in ovariectomized rats.
  • (12) United States Patent (10) Patent No.: US 9.498,431 B2 Xu Et Al

    (12) United States Patent (10) Patent No.: US 9.498,431 B2 Xu Et Al

    USOO9498431B2 (12) United States Patent (10) Patent No.: US 9.498,431 B2 Xu et al. (45) Date of Patent: Nov. 22, 2016 (54) CONTROLLED RELEASING COMPOSITION 7,053,134 B2 * 5/2006 Baldwin et al. .............. 522,154 2004/0058056 A1 3/2004 Osaki et al. ................... 427.2.1 (76) Inventors: Jianjian Xu, Hefei (CN); Shiliang 2005/0037047 A1 2/2005 Song Wang, Hefei (CN); Manzhi Ding 2007/0055364 A1* 3/2007 Hossainy .................. A61F 2/82 s: s s 623, 1.38 Hefei (CN) 2008/0274194 A1* 11/2008 Miller .................... A61K 9.146 424/489 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 0 days. CN 1208.610 A 2, 1999 (21) Appl. No.: 13/133,656 EP O251680 A2 1, 1988 JP S63-22516. A 1, 1988 JP H1O-310518 A 11, 1998 (22) PCT Filed: Dec. 10, 2009 WO 96,10395 A1 4f1996 WO WO 2005.000277 A1 * 1, 2005 (86). PCT No.: PCT/CN2009/075468 WO 2007 115045 A2 10, 2007 WO 2008/OO2657 A2 1, 2008 S 371 (c)(1), WO 2008OO2657 A2 1, 2008 (2), (4) Date: Jun. 9, 2011 WO 2008041246 A2 4/2008 (87) PCT Pub. No.: WO2010/066203 OTHER PUBLICATIONS PCT Pub. Date: Jun. 17, 2010 Crowley and Zhang, Pharmaceutical Application of Hot Melt Extru (65) Prior Publication Data sion: Part I, Drug Development and Industrial Pharmacy, 2007. 33:909-926.* US 2011/024.4043 A1 Oct. 6, 2011 The Use of Poly (L-Lactide) and RGD Modified Microspheres as Cell Carriers in a Flow Intermittency Bioreactor for Tissue Engi (30) Foreign Application Priority Data neering Cartilage.
  • Long-Term Menopausal Treatment Using an Ultra-High Dosage of Tibolone in an Elderly Chinese Patient – Case Report

    Long-Term Menopausal Treatment Using an Ultra-High Dosage of Tibolone in an Elderly Chinese Patient – Case Report

    Long-term menopausal treatment using an ultra-high dosage of tibolone in an elderly Chinese patient – Case report Lingyan Zhang 1, Xiangyan Ruan 1,2*, Muqing Gu 1, Alfred O. Mueck 1,2 1 Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China; 2 Department of Women’s Health, University Women’s Hospital and Research Centre for Women’s Health, University of Tuebingen, Tuebingen D-72076, Germany) ABSTRACT This report describes the special case of a Chinese woman with severe vasomotor symptoms (VSMs), depressed mood, low energy and genitourinary syndrome of menopause, including problems of sexual dysfunction, who was treated with tibolone. The aim of the report is to highlight the value of individualizing menopausal hormone therapy (MHT) type and dosage. Since 16 years of previous treatment with various other forms of MHT had not provided satisfactory efficacy in this patient, at the age of 71 years she was prescribed tibolone, starting at the usual lowest dosage of 1.25 mg/day. We gradually had to increase the dosage of tibolone up to 7.5 mg/day, which is three-fold the recommended maximum dosage. We added three-monthly sequential dydrogesterone to reduce the risk of breakthrough bleeding and the risk of endometrial cancer. To date, we have observed no side effects and no remarkable abnormal laboratory assessments, with the exception of increased thyroid-stimulating hormone, which we monitor six-monthly. Even though the patient has been informed about potential risks, such as increased risks of stroke, breast cancer and endometrial cancer, as described in the discussion, she has now been willing to accept this ultra-high dosage for seven years, and wishes to continue with this treatment.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • Appendix 1 – Protocol for Preventing Or Reversing Chronic Disease The

    Appendix 1 – Protocol for Preventing Or Reversing Chronic Disease The

    Appendix 1 – Protocol for Preventing or Reversing Chronic Disease The first author has developed a protocol over the past decade for preventing or reversing chronic disease based on the following systemic medical principle: “at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective”[1]. The protocol methodology refines the age-old principles of both reducing harm in addition to providing treatment, and allows better identification of factors that contribute to the disease process (so that they may be eliminated if possible). These contributing factors are expansive and may include a combination of Lifestyle choices (diet, exercise, smoking), iatrogenic and biotoxin exposures, environmental/occupational exposures, and psychosocial stressors. This strategy exploits the existing literature to identify patterns of biologic response using biomarkers from various modalities of diagnostic testing to capture a much broader list of potential contributing factors. Existing inflammatory bowel diseases (IBD) Biomarker Identification to Remove Contributing Factors and Implement Treatment The initial protocol steps are diagnostic. The main output of these diagnostics will be identification of the biomarker levels and symptoms that reflect abnormalities, and the directions of change required to eliminate these abnormalities. In the present study, hundreds of general and specific biomarkers and symptoms were identified from the core IBD literature. The highest frequency (based on numbers of record appearances) biomarkers and symptoms were extracted, and are listed in Table 1 (highest frequency items first, reading down each column before proceeding to the next column). They are not necessarily consensus biomarkers. They are biomarkers whose values were altered by a treatment or contributing factor, and reported in the core IBD literature.
  • Review Article New Insight Into Adiponectin Role in Obesity and Obesity-Related Diseases

    Review Article New Insight Into Adiponectin Role in Obesity and Obesity-Related Diseases

    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 658913, 14 pages http://dx.doi.org/10.1155/2014/658913 Review Article New Insight into Adiponectin Role in Obesity and Obesity-Related Diseases Ersilia Nigro,1 Olga Scudiero,1,2 Maria Ludovica Monaco,1 Alessia Palmieri,1 Gennaro Mazzarella,3 Ciro Costagliola,4 Andrea Bianco,5 and Aurora Daniele1,6 1 CEINGE-Biotecnologie Avanzate Scarl, Via Salvatore 486, 80145 Napoli, Italy 2 Dipartimento di Medicina Molecolare e Biotecnologie Mediche, UniversitadegliStudidiNapoliFedericoII,` Via De Amicis 95, 80131 Napoli, Italy 3 Dipartimento di Scienze Cardio-Toraciche e Respiratorie, Seconda Universita` degli Studi di Napoli, Via Bianchi 1, 80131 Napoli, Italy 4 Cattedra di Malattie dell’Apparato Visivo, Dipartimento di Medicina e Scienze della Salute, UniversitadelMolise,` ViaDeSanctis1,86100Campobasso,Italy 5 Cattedra di Malattie dell’Apparato Respiratorio, Dipartimento di Medicina e Scienze della Salute, UniversitadelMolise,` ViaDeSanctis1,86100Campobasso,Italy 6 Dipartimento di Scienze e Tecnologie Ambientali Biologiche Farmaceutiche, Seconda UniversitadegliStudidiNapoli,` Via Vivaldi 42, 81100 Caserta, Italy Correspondence should be addressed to Aurora Daniele; [email protected] Received 2 April 2014; Accepted 12 June 2014; Published 7 July 2014 Academic Editor: Beverly Muhlhausler Copyright © 2014 Ersilia Nigro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution,
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction

    Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction

    pharmaceutics Review Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction Maria D. Auxtero 1, Susana Chalante 1,Mário R. Abade 1 , Rui Jorge 1,2,3 and Ana I. Fernandes 1,* 1 CiiEM, Interdisciplinary Research Centre Egas Moniz, Instituto Universitário Egas Moniz, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal; [email protected] (M.D.A.); [email protected] (S.C.); [email protected] (M.R.A.); [email protected] (R.J.) 2 Polytechnic Institute of Santarém, School of Agriculture, Quinta do Galinheiro, 2001-904 Santarém, Portugal 3 CIEQV, Life Quality Research Centre, IPSantarém/IPLeiria, Avenida Dr. Mário Soares, 110, 2040-413 Rio Maior, Portugal * Correspondence: [email protected]; Tel.: +35-12-1294-6823 Abstract: Late-life mild cognitive impairment and dementia represent a significant burden on health- care systems and a unique challenge to medicine due to the currently limited treatment options. Plant phytochemicals have been considered in alternative, or complementary, prevention and treat- ment strategies. Herbals are consumed as such, or as food supplements, whose consumption has recently increased. However, these products are not exempt from adverse effects and pharmaco- logical interactions, presenting a special risk in aged, polymedicated individuals. Understanding pharmacokinetic and pharmacodynamic interactions is warranted to avoid undesirable adverse drug reactions, which may result in unwanted side-effects or therapeutic failure. The present study reviews the potential interactions between selected bioactive compounds (170) used by seniors for cognitive enhancement and representative drugs of 10 pharmacotherapeutic classes commonly prescribed to the middle-aged adults, often multimorbid and polymedicated, to anticipate and prevent risks arising from their co-administration.
  • Natural Product Standards (1)

    Natural Product Standards (1)

    Natural Product Standards (1) Group Name Product Name CAS No Purity Storage Cat. No. PKG Size List Price ($) Soy Bean Daidzein 486-66-8 98% (HPLC) R NH010102 10 mg 58.00 NH010103 100 mg 344.00 Glycitein 40957-83-3 98% (HPLC) R NH010202 10 mg 156.00 NH010203 100 mg 1,130.00 Genistein 446-72-0 98% (HPLC) R NH010302 10 mg 58.00 NH010303 100 mg 219.00 Daidzin 552-66-9 98% (HPLC) R NH012102 10 mg 138.00 NH012103 100 mg 1,130.00 Glycitin 40246-10-4 98% (HPLC) R NH012202 10 mg 156.00 NH012203 100 mg 1,130.00 Genistin 529-59-9 98% (HPLC) R NH012302 10 mg 156.00 NH012303 100 mg 1,130.00 6" -O-Acetyldaidzin 71385-83-6 98% (HPLC) F NH013101 1 mg 173.00 6" -O-Acetylglycitin 134859-96-4 98% (HPLC) F NH013201 1 mg 173.00 6" -O-Acetylgenistin 73566-30-0 98% (HPLC) F NH013301 1 mg 173.00 6" -O-Malonyldaidzin 124590-31-4 98% (HPLC) F NH014101 1 mg 173.00 6" -O-Malonylglycitin 137705-39-6 98% (HPLC) F NH014201 1 mg 173.00 6" -O-Malonylgenistin 51011-05-3 98% (HPLC) F NH014301 1 mg 173.00 Isoflavone Aglycon Mixture B Total 95% (HPLC) RT NH015204 1 g 344.00 Isoflavone Glucoside Mixture A Total 95% (HPLC) RT NH016104 1 g 346.00 8-Hydroxydaidzein 75187-63-2 98% (HPLC) R NH017102 5 mg 415.00 8-Hydroxyglycitein 113762-90-6 98% (HPLC) R NH017202 5 mg 415.00 8-Hydroxygenistein 13539-27-0 98% (HPLC) R NH017302 5 mg 415.00 Green Tea (-) -Epicatechin 〔(-) -EC 〕 490-46-0 99% (HPLC) R NH020102 10 mg 92.00 NH020103 100 mg 507.00 (-) -Epigallocatechin 〔(-) -EGC 〕 970-74-1 99% (HPLC) R NH020202 10 mg 138.00 NH020203 100 mg 761.00 (-) -Epicatechin gallate 〔(-) -ECg 〕 1257-08-5
  • Metabolic Enzyme/Protease

    Metabolic Enzyme/Protease

    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.